Prasterone | CAS#53-43-0 | steroid

MedKoo Cat#: 585021 | Name: Prasterone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Prasterone is a major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY.

Chemical Structure

Prasterone

CAS#53-43-0

Theoretical Analysis

MedKoo Cat#: 585021

Name: Prasterone

CAS#: 53-43-0

Chemical Formula: C19H28O2

Exact Mass: 288.2089

Molecular Weight: 288.43

Elemental Analysis: C, 79.12; H, 9.79; O, 11.09

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Prasterone; EM-760; GL 701

IUPAC/Chemical Name

Androst-5-en-17-one, 3-beta-hydroxy-

InChi Key

FMGSKLZLMKYGDP-USOAJAOKSA-N

InChi Code

InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1

SMILES Code

C[C@]1([C@](CC2)([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC1)C2=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 288.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mannella P, Simoncini T, Caretto M, Genazzani AR. Dehydroepiandrosterone and Cardiovascular Disease. Vitam Horm. 2018;108:333-353. doi: 10.1016/bs.vh.2018.05.001. Epub 2018 Jul 13. PubMed PMID: 30029733. 2: Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause. Menopause. 2017 Nov;24(11):1246-1256. doi: 10.1097/GME.0000000000000910. PubMed PMID: 28640161. 3: Sauer U, Talaulikar V, Davies MC. Efficacy of intravaginal dehydroepiandrosterone (DHEA) for symptomatic women in the peri- or postmenopausal phase. Maturitas. 2018 Oct;116:79-82. doi: 10.1016/j.maturitas.2018.07.016. Epub 2018 Jul 31. Review. PubMed PMID: 30244783. 4: Archer DF, Labrie F, Montesino M, Martel C. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2017 Nov;174:1-8. doi: 10.1016/j.jsbmb.2017.03.014. Epub 2017 Mar 18. Review. PubMed PMID: 28323042. 5: Labrie F, Bélanger A, Pelletier G, Martel C, Archer DF, Utian WH. Science of intracrinology in postmenopausal women. Menopause. 2017 Jun;24(6):702-712. doi: 10.1097/GME.0000000000000808. Review. PubMed PMID: 28098598. 6: Litwack G. Preface. Vitam Horm. 2018;108:xvii-xviii. doi: 10.1016/S0083-6729(18)30062-1. PubMed PMID: 30029739. 7: Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecol Endocrinol. 2016;32(3):240-5. doi: 10.3109/09513590.2015.1110140. Epub 2016 Jan 6. PubMed PMID: 26634942. 8: Kocis P. Prasterone. Am J Health Syst Pharm. 2006 Nov 15;63(22):2201-10. Review. PubMed PMID: 17090740. 9: Prasterone (Intrarosa) for dyspareunia. Med Lett Drugs Ther. 2017 Sep 11;59(1529):149-150. PubMed PMID: 28880846. 10: Handelsman DJ, Matsumoto AM, Gerrard DF. Doping Status of DHEA Treatment for Female Athletes with Adrenal Insufficiency. Clin J Sport Med. 2017 Jan;27(1):78-85. doi: 10.1097/JSM.0000000000000300. Review. PubMed PMID: 26844622. 11: do Vale S, Escera C. Dehydroepiandrosterone and Dehydroepiandrosterone-Sulfate and Emotional Processing. Vitam Horm. 2018;108:413-441. doi: 10.1016/bs.vh.2018.01.022. Epub 2018 Mar 9. PubMed PMID: 30029737. 12: Vegliante R, Ciriolo MR. Autophagy and Autophagic Cell Death: Uncovering New Mechanisms Whereby Dehydroepiandrosterone Promotes Beneficial Effects on Human Health. Vitam Horm. 2018;108:273-307. doi: 10.1016/bs.vh.2018.01.006. Epub 2018 Feb 21. Review. PubMed PMID: 30029730. 13: Huang K, Wu LD, Bao JP. Dehydroepiandrosterone and Experimental Osteoarthritis. Vitam Horm. 2018;108:367-384. doi: 10.1016/bs.vh.2018.01.021. Epub 2018 Feb 19. PubMed PMID: 30029735. 14: Labrie F, Martel C, Bérubé R, Côté I, Labrie C, Cusan L, Gomez JL. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol. 2013 Nov;138:359-67. doi: 10.1016/j.jsbmb.2013.08.002. Epub 2013 Aug 14. PubMed PMID: 23954500. 15: Quinn T, Greaves R, Badoer E, Walker D. DHEA in Prenatal and Postnatal Life: Implications for Brain and Behavior. Vitam Horm. 2018;108:145-174. doi: 10.1016/bs.vh.2018.03.001. Epub 2018 May 3. Review. PubMed PMID: 30029725. 16: Ke S, Shi L, Zhang Z, Yang Z. Steroidal[17,16-d]pyrimidines derived from dehydroepiandrosterone: A convenient synthesis, antiproliferation activity, structure-activity relationships, and role of heterocyclic moiety. Sci Rep. 2017 Mar 14;7:44439. doi: 10.1038/srep44439. PubMed PMID: 28290501; PubMed Central PMCID: PMC5349525. 17: Meno-Tetang GM, Blum RA, Schwartz KE, Jusko WJ. Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. J Clin Pharmacol. 2001 Nov;41(11):1195-205. PubMed PMID: 11697752. 18: Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J; VVA Prasterone Group. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015 Sep;22(9):950-63. doi: 10.1097/GME.0000000000000428. PubMed PMID: 25734980. 19: Portman DJ, Labrie F, Archer DF, Bouchard C, Cusan L, Girard G, Ayotte N, Koltun W, Blouin F, Young D, Wade A, Martel C, Dubé R; other participating members of VVA Prasterone Group. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015 Dec;22(12):1289-95. doi: 10.1097/GME.0000000000000470. PubMed PMID: 25968836. 20: Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009 Sep-Oct;16(5):907-22. doi: 10.1097/gme.0b013e31819e8e2d. PubMed PMID: 19436225.